Antithrombotic Therapy for VTE Disease

ACCP VTE Therapy

ACCP GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/86135

Contents of this Issue

Navigation

Page 4 of 17

Table 1. Risk Factors for Extension (2-C) Positive D-dimer Thrombosis that is extensive or close to the proximal veins (eg, > 5 cm in length, involves multiple veins, > 7 mm in maximum diameter) No reversible provoking factor for DVT Active cancer History of VTE Inpatient status Acute Leg DVT Confirmed isolated distal DVT Symptoms severe Extension risk Symptoms not severe No extension risk Serial imaging x 2 wks Thrombus extension If bleed risk resolves Confirmed proximal DVT Bleed risk IVC filter VKA x ≥ 5d and INR ≥ 2.0 x > 24h Compression ockings Surgical or other transient factor Unprovoked Active cancer AND LMWH daily or fondaparinux (or IV or subcut UFH) ambulation Early Duration of Anticoagulation for LE DVT 3 months ≥ 3 months ≥ 3 months 3

Articles in this issue

Archives of this issue

view archives of Antithrombotic Therapy for VTE Disease - ACCP VTE Therapy